Skip to Content

Join the 'Thrombotic / Thromboembolic Disorder' group to help and get support from people like you.

Thrombotic / Thromboembolic Disorder News

Related terms: Budd-Chiari syndrome, Hepatic vein obstruction, Budd-Chiari, Factor V Leiden, Prothrombin G20210A Mutation

FDA Approves Defitelio (defibrotide sodium) for Hepatic Veno-Occlusive Disease Following Hematopoietic Stem-Cell Transplantation

Posted 31 Mar 2016 by Drugs.com

March 30, 2016 – The U.S. Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT). This is the first FDA-approved therapy for treatment of severe hepatic VOD, a rare and life-threatening liver condition. HSCT is a procedure performed in some patients to treat certain blood or bone marrow cancers. Immediately before an HSCT procedure, a patient receives chemotherapy. Hepatic VOD can occur in patients who receive chemotherapy and HSCT. Hepatic VOD is a condition in which some of the veins in the liver become blocked, causing swelling and a decrease in blood flow inside the liver, which may lead to liver damage. In the most ... Read more

Related support groups: Thrombotic/Thromboembolic Disorder, Defitelio, Defibrotide

Drug May Be Antidote to Bleeding Tied to Blood Thinner Pradaxa

Posted 22 Jun 2015 by Drugs.com

MONDAY, June 22, 2015 – The new blood thinner Pradaxa (dabigatran) is being widely used, but it comes with one serious drawback: rare but dangerous cases of sudden, uncontrolled bleeding in patients. Now, a new study finds than an experimental, injected drug called idarucizumab could be used to quickly stop that bleeding. "Idarucizumab completely reversed the anticoagulant [bleeding] effect of dabigatran within minutes," researchers say in a study published online June 22 in the New England Journal of Medicine. In recent years, new-generation blood thinners such as Pradaxa have been approved as more manageable alternatives to older drugs such as warfarin. Unlike warfarin, these drugs "do not require blood tests for monitoring... while offering similar results in terms of effectiveness," explained Dr. Kevin Marzo, chief of cardiology at Winthrop-University Hospital in Mineola, N.Y. ... Read more

Related support groups: Warfarin, Coumadin, Atrial Fibrillation, Pradaxa, Transient Ischemic Attack, Prosthetic Heart Valves, Prevention of Thromboembolism in Atrial Fibrillation, Prosthetic Heart Valves - Mechanical Valves, Atrial Flutter, Ischemic Stroke - Prophylaxis, Thrombotic/Thromboembolic Disorder, Thromboembolic Stroke Prophylaxis, Prosthetic Heart Valves - Tissue Valves, Jantoven, Dabigatran, Mitral Stenosis, Myocardial Infarction - Prophylaxis, Valvular Heart Disease, Iprivask, Anisindione

Most Treatments for Blood Clots Appear Safe, Effective

Posted 16 Sep 2014 by Drugs.com

TUESDAY, Sept. 16, 2014 – Almost all the various treatment options for blood clots that form in veins are equally safe and effective, new research shows. In exploring the safety and effectiveness of treatments for such blood clots as deep vein thrombosis or pulmonary embolism (blood clot in a lung), Canadian researchers analyzed outcomes associated with eight blood-thinning options, including unfractionated heparin, low-molecular-weight heparin (LMWH) and fondaparinux in combination with vitamin K antagonists. The investigators also examined LMWH with dabigatran (Pradaxa), edoxaban, rivaroxaban (Xarelto), apixaban (Eliquis), as well as LMWH alone. After examining nearly 50 randomized studies, the researchers found that unfractionated heparin combined with vitamin K antagonist was associated with a higher percentage of recurrent blood clots over the course of three months than the ... Read more

Related support groups: Xarelto, Deep Vein Thrombosis (DVT), Pradaxa, Pulmonary Embolism, Eliquis, Deep Vein Thrombosis, Heparin, Rivaroxaban, Apixaban, Thrombotic/Thromboembolic Disorder, Arixtra, Hep-Pak, Fondaparinux, Dabigatran, Venous Thromboembolism, Pulmonary Thromboembolism, Heparin Sodium, Arixtra 7.5 mg/dose, Hep-Pak CVC, Arixtra 5 mg/dose

FDA Medwatch Alert: Heparin Sodium, 1,000 USP Heparin Units/500 mL (2 USP Heparin Units/mL), In 0.9 percent Sodium Chloride Injection, 500 mL by Hospira: Recall - Particulate Matter

Posted 15 Sep 2014 by Drugs.com

ISSUE: Hospira, Inc. announced a voluntary nationwide user-level recall of one lot of Heparin Sodium, 1,000 USP Heparin Units/500 mL (2 USP Heparin Units/mL), in 0.9% Sodium Chloride Injection, 500 mL, NDC 0409-7620-03 Lot 41-046-JT with expiration date of 01NOV 2015. This action is due to one confirmed customer report of particulate in a single unit. The foreign particle was confirmed by Hospira as human hair, sealed between the tube and the film at the round seal of the unused Administrative Port on the non-print side of the container. Injected particulate material may result in local inflammation, phlebitis, and/or low-level allergic response. Capillaries which may be as small as the size of a red blood cell, approximately seven microns in diameter, may become occluded. Patients with preexisting condition of trauma or other medical condition that adversely affects the microvascular ... Read more

Related support groups: Heparin, Thrombotic/Thromboembolic Disorder, Hep-Pak, Heparin Sodium, Hep-Pak CVC

C-Sections Linked to Doubled Risk for Blood Clots

Posted 26 Aug 2011 by Drugs.com

FRIDAY, Aug. 26 – The risk of thromboembolism – a potentially fatal condition in which blood clots block blood flow causing damage to the organs – is higher during pregnancy, experts warn. And having a Caesarean section nearly doubles that risk, according to experts at the American College of Obstetricians and Gynecologists. As a result, the group issued a new recommendation that all women having a C-section wear inflatable compression devices on their legs at the time of delivery to prevent clots from forming. In more risky cases, the group advised that women also receive anti-clotting medications (anticoagulants). "VTE [venous thromboembolism] is a major contributor to maternal mortality in this country. The risk of VTE is increased during pregnancy and the consequences can be severe," Dr. Andra H. James, who helped develop the guidelines, said in a college news release. "It's ... Read more

Related support groups: Thrombotic/Thromboembolic Disorder, Cesarean Section

Ask a Question

Further Information

Related Condition Support Groups

Thromboembolic Disorder

Related Drug Support Groups

heparin, Activase, streptokinase, alteplase, Heparin Sodium, Cathflo Activase, urokinase, argatroban, Kinlytic, Acova, Abbokinase, Kabikinase, Streptase, Abbokinase Open-Cath